Welcome to our dedicated page for Caredx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on Caredx stock.
CareDx, Inc. (NASDAQ: CDNA) is at the forefront of transforming transplant patient care through its innovative surveillance management solutions. Dedicated to improving the lives of organ transplant patients, CareDx leverages the latest in genomics and bioinformatics technology combined with rigorous clinical evidence derived from trials and registries.
CareDx offers a suite of precision medicine solutions aimed at enhancing both pre- and post-transplant care. One of its flagship products, AlloSure®, is the first and only non-invasive blood test that directly measures allograft injury. This next-generation sequencing (NGS) based test detects donor-derived cell-free DNA (dd-cfDNA), providing clinicians with a powerful tool to identify organ injury and the probability of active rejection, particularly in kidney transplant patients.
The company's portfolio also includes AlloMap Heart, AlloSure Heart, and AlloSure Lung, which are dd-cfDNA solutions designed for heart and lung transplant recipients. These products underscore CareDx’s commitment to offering clinically differentiated, high-value healthcare solutions that span the entire transplant journey.
CareDx generates the majority of its revenue from the United States, with a significant portion coming from its testing services. Its product suite not only addresses the critical needs of transplant patients but also supports healthcare providers in delivering better patient outcomes through genomics-based information.
Recent achievements include the continued expansion of their product line and partnerships with leading healthcare institutions to further validate and implement their innovative diagnostic solutions. These efforts position CareDx as a leader in the field of transplant diagnostics and surveillance.
CareDx, Inc. (Nasdaq: CDNA) announced the release of a final local coverage determination by Palmetto MolDx for AlloSure Heart, a dd-cfDNA test identifying cell injury that leads to organ rejection. Medicare reimbursement for this test follows a thorough technical assessment, highlighting its clinical utility in transplant management. This decision facilitates the launch of HeartCare, which combines AlloSure Heart with AlloMap Heart, offering a comprehensive, non-invasive solution for heart transplant patients during the COVID pandemic. This coverage enhances patient access and optimizes care management.
CareDx, Inc. (Nasdaq: CDNA) launched AlloCare, a mobile app aimed at enhancing medication adherence and health management for transplant patients. The app will debut at the AlloCare Transplant Festival on September 26, 2020, designed to foster connections within the transplant community. The festival will feature notable personalities and over 25 transplant organizations, emphasizing CareDx's commitment to improving long-term outcomes through innovative patient engagement solutions. The app is now available for download in the Apple App Store.
CareDx, Inc. (CDNA) announced its participation in the 28th International Congress of The Transplantation Society (TTS) from September 13-16, 2020. The company will showcase its AlloSure and AlloSeq cfDNA tools through four virtual symposia and six poster presentations. Expert speakers will discuss topics like risk prediction in kidney transplantation and the use of dd-cfDNA as a biomarker. CareDx aims to support continuous education for the transplant community and emphasize innovations in transplant medicine.
CareDx, Inc. (NASDAQ: CDNA), a precision medicine leader, has appointed new senior executives in key areas: Digital Services, Laboratory Operations, Business Development, and Market Access. The appointments aim to enhance operational efficiency amidst rapid growth. Notable new hires include Kashif Rathore, Ryan Phan, Sean Grant, and Danielle Scelfo, each bringing extensive experience from leading companies. CEO Peter Maag emphasizes the need for robust leadership to navigate increasing operational complexities and advance CareDx's market strategies.
CareDx, a precision medicine company, announced that its Chairman and CEO, Peter Maag, will present at the AAKP and George Washington University summit on July 16-17, 2020. The event focuses on innovations in kidney disease, particularly the role of artificial intelligence in transplant care. CareDx aims to enhance patient care through its digital tools, AiTraC and AlloCare, which address information management challenges for transplant patients. The summit highlights the global interest in improving transplant outcomes through data-driven solutions.
CareDx, Inc. (Nasdaq: CDNA) announced the publication of a study in Kidney360 evaluating its AlloSure tool against another monitoring method for kidney transplant rejection. The study, involving 76 patients, indicated that AlloSure provides faster results, with 75% of results delivered at least one day earlier than its counterpart, demonstrating superior accuracy in clinical interpretation. This validation highlights AlloSure's effectiveness in addressing transplant-specific testing needs.
CareDx (Nasdaq: CDNA) announced the full exercise of underwriters' option to purchase an additional 585,937 shares at $32.00 per share, resulting in net proceeds of approximately $17.6 million. This follows a public offering of 3,906,250 shares, which closed on June 15, 2020. With the additional shares, CareDx has sold a total of 4,492,187 shares, generating total net proceeds of around $134.7 million after expenses. The offering was managed by Goldman Sachs & Co. LLC and Jefferies LLC, among others.
CareDx, Inc. (Nasdaq: CDNA) has successfully closed a public offering of 3,906,250 shares of common stock priced at $32.00 per share, generating net proceeds of approximately $117.1 million. The underwriters also have a 30-day option to purchase an additional 585,937 shares. These funds are earmarked for working capital and general corporate purposes. The offering was conducted under a shelf registration statement, effective since June 9, 2020. Goldman Sachs & Co. LLC and Jefferies LLC served as joint book-running managers.
CareDx, Inc. (Nasdaq: CDNA) has announced the pricing of a public offering of 3,906,250 shares at $32.00 per share, aiming for gross proceeds of $125 million. The offering includes a 30-day option for underwriters to purchase an additional 585,937 shares. Expected to close around June 15, 2020, proceeds will support working capital and corporate purposes. The offering is registered under Form S-3ASR with the SEC. Goldman Sachs & Co. LLC and Jefferies LLC are leading the offering.
CareDx, Inc. (Nasdaq: CDNA) announced plans for an underwritten public offering of up to $100 million in its common stock. The company may grant underwriters a 30-day option to purchase an additional $15 million in shares. Proceeds will be used for working capital and general corporate purposes. The offering is contingent on market conditions and is being managed by Goldman Sachs & Co. LLC and Jefferies LLC. The offering is registered under a previously filed shelf registration statement with the SEC, and a preliminary prospectus will be available shortly.
FAQ
What is the current stock price of Caredx (CDNA)?
What is the market cap of Caredx (CDNA)?
What does CareDx, Inc. specialize in?
What is AlloSure®?
Which organs do CareDx's products focus on?
Where does CareDx generate most of its revenue?
What are some key products offered by CareDx?
How does CareDx support transplant patients?
What technology does CareDx use in its diagnostics?
Does CareDx collaborate with other healthcare institutions?
What kind of clinical evidence does CareDx generate?
What makes CareDx a leader in transplant diagnostics?
